Navigation Links
Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
Date:2/6/2008

ross margin of 61% in the same quarter of the previous year due to a less favorable product mix and yields and backorders of higher margin products. Operating expenses for the first quarter of fiscal year 2008 included $1.6 million in costs associated with the proposed merger. Operating expenses were also impacted by $227,000 resulting from the implementation of procedures relating to compliance with the Sarbanes Oxley Act of 2002. The Company is not expected to incur any additional material costs relating to Sarbanes-Oxley for the remaining quarters of fiscal year 2008. During the quarter, the Company incurred $445,000 in SFAS 123(R) stock option expense. For the three months ended December 31, 2007, the net loss totaled $1.3 million or $.07 basic loss per share and $.07 diluted loss per share. Excluding the $1.6 million in costs associated with the proposed merger, the Company would have reported net income of $343,000, or $0.02 per fully diluted share, compared to net income of $361,000, or $0.02 per fully diluted share, in the comparable quarter a year ago.

Guy L. Mayer, Chief Executive Officer of Tutogen Medical, said, "From an operating perspective, we are pleased with the continued double-digit growth in virtually all product and geographic segments. U.S. revenues grew 30%, led by continuing momentum in Surgical Specialties, with a 73% increase, and by a strong 27% increase in domestic dental product revenues."

"We also achieved outstanding growth internationally, with a 32% increase. We believe that our products have the potential to become market leaders internationally, and particularly in Europe. Going forward, as our distribution partners more fully embed our products in international markets, we believe strong and consistent future growth can be achieved."

Mr. Mayer commented on the proposed merger with Regeneration Technologies, Inc. "As the date approaches we very much look forward to the combination of the companies and the signi
'/>"/>

SOURCE Tutogen Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
3. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
4. Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results
5. Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results
6. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015   For the seventh ... sciences to assess their overall digital maturity called the ... that these companies are not maturing fast enough. While ... industry in numerous ways overall and customers are increasingly ... terms of digital customer engagement.  ...
(Date:6/26/2015)... , June 26, 2015  SeraCare Life ... diagnostics manufacturers, today announced that it has signed ... the National Cancer Institute (NCI), part of the ... and positive controls for cancer assays.  The CRADA ... and accurately quantitate control DNA biosynthetics spiked into ...
(Date:6/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... listed in the management information circular dated June 1, ... Meeting of Shareholders, held earlier today, June 26 ... 5 nominees proposed by management were elected as ... Company,s next Annual Meeting of Shareholders or until ...
(Date:6/26/2015)... STRASBURG, Va. , June 26, 2015  A ... release two products made with synthetic rhino horn: beer ... in Vietnam . In response to ... oppose the manufacture, marketing and sale of synthetic rhino ... (IRF) and Save the Rhino International ...
Breaking Biology Technology:Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3Rhino Experts Oppose Synthetic Rhino Horn as Solution to Poaching Crisis 2
... Companies will Present at the Largest Marketplace for Emerging ... and CTSI today announced that more than 100 leading ... partners will be showcased in the 4th Annual TechConnect ... R. Brown Convention Center in Houston, Texas. Held ...
... Development and InnovationMOUNTAIN VIEW, Calif., April 22 ... Pharmaceuticals & Biotechnology group assesses a variety of ... in cancer treatment. Physicians, nurses and patients ... reconstitution, home vs. office administration parameters, and barriers ...
... 22 GeneGo, Inc., a leading provider of software ... , today announced that the University of Cardiff has ... researchers will have access to GeneGo,s MetaCore, training and ... their partner relationship with GeneGo to provide a pathway ...
Cached Biology Technology:TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 2TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 3TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 4Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 2Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 3Cardiff University Becomes a GeneGo Center of Excellence 2
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
(Date:6/24/2015)... 2015 This report provides market analysis of ... years. It contains an analysis of the drivers, challenges, ... impact from the short, medium, and long term perspective ... market, and technology trends that currently, prevail in the ... authorities to efficiently manage the increasing marine traffic and ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... Jos Zanchetta, a member of the IOF Board and ... has been named the recipient of the prestigious Pierre ... Osteoporosis Foundation (IOF) in memory of Pierre D. Delmas, ... growth of the Foundation and osteoporosis advocacy worldwide. ...
... the damage caused by a heart attack survived in the ... a mouse model, researchers at The University of Texas MD ... Circulation Research . The study, with researchers at the ... imaging techniques developed by researchers at MD Anderson to track ...
... a 1600 km-wide ash cloud over the Atlantic. The ... visible in stark contrast to white clouds framing this ... emitting steam and ash on 20 March, wreaking havoc ... week caused some flights to be suspended to and ...
Cached Biology News:Transplanted adult stem cells provide lasting help to injured hearts 2Transplanted adult stem cells provide lasting help to injured hearts 3Transplanted adult stem cells provide lasting help to injured hearts 4
...
cysteine and glycine-rich protein 2,...
... agent and DNA-topoisomersae II inhibitor (IC50 = 59.2 ... C 29 H 32 O 13 ... Store at: RT ... Soluble to 100 mM ...
HSPBP1 Antibody...
Biology Products: